These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 19695319)

  • 1. The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination?
    Lutz WK
    Toxicol Lett; 2009 Nov; 190(3):239-42. PubMed ID: 19695319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
    Müller L; Gocke E; Lavé T; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EMS in Viracept--the course of events in 2007 and 2008 from the non-clinical safety point of view.
    Müller L; Singer T
    Toxicol Lett; 2009 Nov; 190(3):243-7. PubMed ID: 19857794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling of patient EMS exposure: translating pharmacokinetics of EMS in vitro and in animals into patients.
    Lavé T; Paehler A; Grimm HP; Gocke E; Müller L
    Toxicol Lett; 2009 Nov; 190(3):310-6. PubMed ID: 19695316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EMS in Viracept--initial ('traditional') assessment of risk to patients based on linear dose response relations.
    Gocke E; Müller L; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):266-70. PubMed ID: 19439165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What happened: the chemistry side of the incident with EMS contamination in Viracept tablets.
    Gerber C; Toelle HG
    Toxicol Lett; 2009 Nov; 190(3):248-53. PubMed ID: 19857795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Literature review on the genotoxicity, reproductive toxicity, and carcinogenicity of ethyl methanesulfonate.
    Gocke E; Bürgin H; Müller L; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):254-65. PubMed ID: 19857796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MNT and MutaMouse studies to define the in vivo dose response relations of the genotoxicity of EMS and ENU.
    Gocke E; Ballantyne M; Whitwell J; Müller L
    Toxicol Lett; 2009 Nov; 190(3):286-97. PubMed ID: 19446969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. General 4-week toxicity study with EMS in the rat.
    Pfister T; Eichinger-Chapelon A
    Toxicol Lett; 2009 Nov; 190(3):271-85. PubMed ID: 19442710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo and in vitro characterization of ethyl methanesulfonate pharmacokinetics in animals and in human.
    Lavé T; Birnböck H; Götschi A; Ramp T; Pähler A
    Toxicol Lett; 2009 Nov; 190(3):303-9. PubMed ID: 19695315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo studies in the mouse to define a threshold for the genotoxicity of EMS and ENU.
    Gocke E; Müller L
    Mutat Res; 2009 Aug; 678(2):101-7. PubMed ID: 19376265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Considerations regarding a permitted daily exposure calculation for ethyl methanesulfonate.
    Müller L; Gocke E
    Toxicol Lett; 2009 Nov; 190(3):330-2. PubMed ID: 19857798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Viracept-EMS case: impact and outlook.
    Walker VE; Casciano DA; Tweats DJ
    Toxicol Lett; 2009 Nov; 190(3):333-9. PubMed ID: 19866516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo genotoxicity of EMS: statistical assessment of the dose response curves.
    Gocke E; Wall M
    Toxicol Lett; 2009 Nov; 190(3):298-302. PubMed ID: 19857797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing.
    Thybaud V; Aardema M; Clements J; Dearfield K; Galloway S; Hayashi M; Jacobson-Kram D; Kirkland D; MacGregor JT; Marzin D; Ohyama W; Schuler M; Suzuki H; Zeiger E;
    Mutat Res; 2007 Feb; 627(1):41-58. PubMed ID: 17126066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-linear dose-response of DNA-reactive genotoxins: recommendations for data analysis.
    Johnson GE; Doak SH; Griffiths SM; Quick EL; Skibinski DO; Zaïr ZM; Jenkins GJ
    Mutat Res; 2009 Aug; 678(2):95-100. PubMed ID: 19467345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trace determination of ethyl methanesulfonate in Viracept 250 mg tablets by gas chromatography-mass spectrometry.
    Rebiere H; Maggio AF; Gimeno P; Levaillant D; Civade C; Bonnet PA; Tissier MH
    Pharmeur Sci Notes; 2008 Feb; 2008(1):17-20. PubMed ID: 18430402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-methylpurine DNA glycosylase plays a pivotal role in the threshold response of ethyl methanesulfonate-induced chromosome damage.
    Zaïr ZM; Jenkins GJ; Doak SH; Singh R; Brown K; Johnson GE
    Toxicol Sci; 2011 Feb; 119(2):346-58. PubMed ID: 21071726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical model to estimate a threshold dose and its confidence limits for the analysis of sublinear dose-response relationships, exemplified for mutagenicity data.
    Lutz WK; Lutz RW
    Mutat Res; 2009 Aug; 678(2):118-22. PubMed ID: 19477296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative dose-response analysis of ethyl methanesulfonate genotoxicity in adult gpt-delta transgenic mice.
    Cao X; Mittelstaedt RA; Pearce MG; Allen BC; Soeteman-Hernández LG; Johnson GE; Bigger CA; Heflich RH
    Environ Mol Mutagen; 2014 Jun; 55(5):385-99. PubMed ID: 24535894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.